EBS - Emergent BioSolutions Inc.

NYSE - NYSE Delayed Price. Currency in USD

Emergent BioSolutions Inc.

400 Professional Drive
Gaithersburg, MD 20879
United States
240-631-3200
http://www.emergentbiosolutions.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees1,098

Key Executives

NameTitlePayExercisedAge
Mr. Fuad El-HibriFounder and Exec. Chairman971.56k2.26M59
Mr. Daniel J. Abdun-NabiChief Exec. Officer, Pres and Director1.24MN/A62
Mr. Robert G. Kramer Sr.Chief Financial Officer, Exec. VP of Admin. and Treasurer715.49k1.13M60
Mr. Adam R. HaveyExec. VP of Bus. Operations and Pres of Biodefense Division589.31k1.15M46
Dr. W. James Jackson Ph.D.Chief Scientific Officer and Sr. VPN/AN/A62
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company’s marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. Its investigational stage product candidates include NuThrax, a next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072 for Burkholderia pseudomallei; FLU-IG (NP025), a human polyclonal antibody therapeutic being developed to treat seasonal influenza; ZIKA-IG (NP024), a human polyclonal antibody therapeutic being developed as a prophylaxis for Zika infections; and FILOV (NP026), an equine polyclonal antibody therapeutic being developed to treat Ebola infections. In addition, the company provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

Emergent BioSolutions Inc.’s ISS Governance QualityScore as of September 1, 2017 is 5. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.